Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
Completed
Sanofi
Phase 3
2005-04-01
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and
effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with
type 1 diabetes mellitus.
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
Completed
Sanofi
Phase 3
2004-04-01
The purpose of this study is to compare the change in glycemic control, as measured by
hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin
glulisine as mealtime insulin following a variable bolus insulin regimen (based on
carbohydrate counting) versus a fixed bolus insulin regimen, with insulin glargine as basal
insulin in both arms of the study.
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
Completed
Sanofi
Phase 3
2004-08-01
The purpose of this study is to show the non-inferiority of insulin glulisine administered
with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c
(HbA1c), from baseline to study week 24.
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
Completed
Sanofi
Phase 3
2004-08-01
The purpose of this study is to compare the change in weight from baseline to study week 52
in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal
Apidra, in patients receiving insulin glargine (Lantus) as basal insulin.
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
Completed
Sanofi
Phase 3
2005-08-01
The purpose of this study is to test for superiority in improvements from baseline in patient
reported outcomes in subjects with type 1 or type 2 diabetes when treated with insulin
glargine plus rapid acting insulin glulisine MDI versus treatment with premix insulin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
